CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Moderna, the biotech company behind one of the original mRNA COVID-19 vaccines, is undergoing an AI-powered workplace ...

Moderna, Inc. (NASDAQ:MRNA) announced on Friday that it has submitted a marketing application to the U.S. Food and Drug ...

In 2023, the federal Biomedical Advanced Research and Development Authority, part of HHS, requested proposals from Moderna and other companies to develop mRNA vaccines for potential public health ...

Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA ...

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

The U.S. government is giving drugmaker Moderna $176 million to ... in dairy cows across the country. The vaccine is in the early stages of development and would not be available until at least ...

Kennedy Jr, could imperil the development of this and other ... that the mRNA covid-19 vaccine was the “deadliest vaccine ever made.” Moderna stated last week it doesn’t expect its mRNA ...

The biotech has deprioritized the development of mRNA-1083 in people aged 18 to 49 years. Moderna is still working to get the vaccine to older adults, but the process is taking longer than hoped.